Published in Cancer Weekly, July 22nd, 2003
"The therapeutic effect of a human leucocyte antigen (HLA)-identical allogeneic stem cell transplantation (allo-SCT) for the treatment of hematological malignancies is mediated partly by the allogeneic T cells that are administered together with the stem cell graft," scientists in the Netherlands explained. "Chronic myeloid leukemia (CML) is particularly sensitive to this graft-versus-leukemia (GVL) effect."
"Several studies have shown that in allogeneic responses both CD4 and CD8 cells are capable of strong antigen-specific growth inhibition of leukemic progenitor cells, but that CD4 cells mainly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.